Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Brainsway ( (BWAY) ) has provided an announcement.
On February 17, 2026, BrainsWay announced that its board approved a change in the ratio of its American Depositary Shares listed on Nasdaq to its ordinary shares traded in Tel Aviv, shifting from a 2‑to‑1 ordinary share‑to‑ADS structure to a 1‑to‑1 alignment effective March 3, 2026. The adjustment will function as a 2‑for‑1 forward split for ADS holders, leaving ordinary shares unchanged and expected to halve the ADS trading price while doubling the number of ADSs per holder.
The company says the move is intended to simplify comparisons between its U.S. and Israeli listings, streamline its capital structure, and give investors a clearer view of its valuation across markets. Management also expects the new ADS ratio to improve trading liquidity and accessibility for U.S. investors, potentially broadening the shareholder base and supporting BrainsWay’s positioning as a dual‑listed neurotechnology player.
The most recent analyst rating on (BWAY) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Brainsway stock, see the BWAY Stock Forecast page.
Spark’s Take on BWAY Stock
According to Spark, TipRanks’ AI Analyst, BWAY is a Outperform.
The score is driven primarily by improved profitability, strong cash generation, and a low-leverage balance sheet, reinforced by raised guidance and strong Q3 operating momentum. These positives are tempered by a demanding P/E valuation and technically stretched momentum signals that raise near-term pullback risk.
To see Spark’s full report on BWAY stock, click here.
More about Brainsway
BrainsWay Ltd. is a medical technology company specializing in advanced noninvasive neurostimulation treatments for mental health disorders. Using its proprietary Deep Transcranial Magnetic Stimulation platform, the company offers FDA‑cleared therapies for major depressive disorder, obsessive‑compulsive disorder, and smoking addiction, and runs additional clinical trials in psychiatric, neurological, and addiction indications.
Average Trading Volume: 90,799
Technical Sentiment Signal: Buy
Current Market Cap: $453.7M
Find detailed analytics on BWAY stock on TipRanks’ Stock Analysis page.